Clinical Trial Results: Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PD-1 blockade with a dendritic cell/AML vaccine following chemotherapy-induced remission in acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• PD-1 blockade
• dendritic cell/AML vaccine

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Acute Myelogenous Leukemia, AML | Phase 2 | Status: COMPLETED | Results posted: 2026-07-14